Clinical Value of Serum miRNA in Patients with Acute Promyelocytic Leukemia
- PMID: 35401744
- PMCID: PMC8993542
- DOI: 10.1155/2022/7315879
Clinical Value of Serum miRNA in Patients with Acute Promyelocytic Leukemia
Abstract
Objective: To explore the clinical value of specific miRNA in patients with acute promyelocytic leukemia.
Methods: 129 patients with acute promyelocytic leukemia diagnosed in our hospital from January 2015 to January 2020 were selected as the observation group. At the same time, 74 patients with nonacute promyelocytic leukemia who underwent bone marrow aspiration were included as the control group. The expression levels of miR-126-5p and miR-13, different characteristic parameters, and prognosis were compared between the two groups, and the clinical significance of miR-126-5p and miR-13 in acute promyelocytic leukemia was analyzed.
Results: The expression of miR-126-5p (12.31 ± 2.25 versus 17.30 ± 3.28) and miR-13 (16.05 ± 3.47 versus 21.66 ± 2.18) in the observation group was significantly lower than that in the control group (P < 0.05). The expression level of miR-126-5p was significantly correlated with lactate dehydrogenase level, HGB level, NPM1 mutant type, and complete remission (P < 0.05). The expression level of miR-13 was significantly correlated with HGB level, NPM1 mutant type, and complete remission (P < 0.05). Both expression levels of miR-126-5p and miR-13 were not correlated with sex, age, WBC, PLT, proportion of bone marrow primordial cells, hepatomegaly, splenomegaly, lymph node enlargement, and FLT3-ITD (P > 0.05). Cox multivariate regression analysis showed that peripheral blood WBC, bone marrow blast cell count, and miR-126-5p and miR-13 were prognostic factors in patients with acute promyelocytic leukemia (P < 0.05). The sensitivity, specificity, accuracy, and AUC of serum miR-126-5p prediction were 75.83%, 84.56%, 82.17%, and 0.729, respectively. The sensitivity, specificity, accuracy, and AUC of serum miR-13 prediction were 78.64%, 88.49%, 86.20% and 0.882, respectively.
Conclusion: Serum miR-126-5p and miR-13 are closely related to the prognosis of patients with acute promyelocytic leukemia. Serum miR-126-5p and miR-13 can be used as reliable indexes to predict the prognosis of patients.
Copyright © 2022 Bei Zhang et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures



Similar articles
-
CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.Hum Pathol. 2013 Oct;44(10):2038-46. doi: 10.1016/j.humpath.2013.03.007. Epub 2013 May 21. Hum Pathol. 2013. PMID: 23701943
-
[Value of serum miR-155-5p and miR-133a-3p expression for the diagnosis and prognosis evaluation of sepsis].Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016 Aug;28(8):694-8. doi: 10.3760/cma.j.issn.2095-4352.2016.08.005. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016. PMID: 27434558 Chinese.
-
[Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].Zhonghua Xue Ye Xue Za Zhi. 2008 Nov;29(11):757-61. Zhonghua Xue Ye Xue Za Zhi. 2008. PMID: 19176014 Chinese.
-
[Significance of microRNA 216a, 324-5p and 29a expression in peripheral blood in patients with acute pancreatitis and their correlation with liver injury].Zhonghua Yi Xue Za Zhi. 2020 Jul 21;100(27):2126-2131. doi: 10.3760/cma.j.cn112137-20200103-00016. Zhonghua Yi Xue Za Zhi. 2020. PMID: 32689754 Chinese.
-
Regulation of the MIR155 host gene in physiological and pathological processes.Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Gene. 2013. PMID: 23246696 Review.
References
-
- Pourbagheri-Sigaroodi A., Bashash D., Safaroghli-Azar A., et al. Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line. European Journal of Pharmacology . 2019;846:49–62. doi: 10.1016/j.ejphar.2019.01.018. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous